Book A Strategy Call
15-minute discovery call. No commitment required.
Oncology PA Case Study
4.9 ★★★★★ Google Rating

Oncology Infusion PA: From 6-Day Wait to Under 36-Hour Turnaround

This outsourced prior authorization case study covers a 14-provider community oncology infusion center that was losing chair time and writing off J-code drugs after retroactive denials. After engaging Staffingly’s dedicated remote PA team,  a HIPAA-compliant healthcare BPO with named specialists, not a shared offshore pool,  average turnaround dropped to under 36 hours, first-pass approvals climbed to 87%, and the practice protected an estimated $1.4M in quarterly J-code revenue.

<36hAverage PA turnaround
87%First-pass approval rate
64%Denial overturn on appeal

See Your Oncology PA Backlog Cleared in 2 Weeks

Free assessment, no obligation, no high-pressure pitch.

Trusted by 800+ Providers MGMA 2026 Corporate Member HIPAA Compliant SOC 2 Type II BAA Signed $5M Insured
Case Studies
Ask AI About This Page

Practice Type
Community Oncology + Infusion Center
Size
14 providers, 22 infusion chairs, 3 sites
Geography
Midwest and Southeast US
EHR / Systems
OncoEMR / iKnowMed plus payer portals
The Challenge

What happens when oncology prior authorization is handled in-house without dedicated outsourcing?

Community oncology lives or dies on infusion chair utilization. Every J-code drug administered without an approved prior authorization is a write-off waiting to happen, and every delayed chemotherapy start is a clinical risk the medical director must defend. This 14-provider infusion center was facing both problems simultaneously,  and the root cause was an overwhelmed in-house PA workflow with no systematic structure.

“Physicians complete an average of 39 prior authorization requests per week and spend roughly 13 hours of clinical and clerical time on them.” AMA Prior Authorization Physician Survey, 2024

Before outsourcing prior authorization to Staffingly, two full-time staff were processing nothing but PA requests. The medical director was still personally writing letters of medical necessity for biologics and targeted therapies on weekends. Three failure modes kept repeating.

1

Inconsistent NCCN citations

The same regimen would be approved by one reviewer and denied by another because guideline citations were not standardized across requests.

2

Incomplete clinical packets

No clean intake process for capturing pathology, staging, biomarker results, and prior therapy history at the point of order. Packets were assembled twice.

3

Reactive P2P scheduling

Peer-to-peer requests piled up because no single person owned the calendar. Recovery was weeks, not days.

Financial exposure: KFF’s 2024 Medicare Advantage analysis found plans denied 7.7% of 53 million PA requests,  with denial rates reaching 12.8% at some major insurers. For oncology, even a 5% retroactive denial rate on J-code drugs can wipe out the margin on an entire infusion suite. CMS-0057-F (effective 2026) mandates 7-day standard and 72-hour expedited decisions,  the practice’s manual workflow could not meet that standard.

The Staffingly Solution

How does outsourced prior authorization work for an oncology infusion center?

Staffingly stood up a dedicated oncology PA pod within 10 business days. The pod operates as a tiered outsourced team: overseas-licensed MDs and pharmacists own clinical packet assembly and NCCN guideline citations; trained remote virtual medical assistants run payer portals and fax workflows; a US-facing coordinator handles peer-to-peer scheduling and real-time escalations with the practice’s oncologists.

1

Intake redesign

Every infusion order triggers a single PA worksheet capturing ICD-10, J-code, regimen line, biomarker results, prior therapy failures, and NCCN compendia citations,  locked before it leaves the practice.

2

Payer-specific playbooks

Living documentation for the top 12 commercial and Medicare Advantage payers: portal quirks, fax vs portal preference, required attachments, and known denial patterns by J-code. Updated same day when payer policy changes.

3

P2P desk ownership

One coordinator owns a single calendar across all 14 providers, books peer-to-peer slots within 48 hours of any denial, and pre-loads each physician with a denial brief including NCCN page citations and counter-arguments.

“Manual prior authorizations cost the industry roughly $93,000 per physician per year. Automation and structured outsourcing is where most of those savings land.” CAQH 2024 Index

Compliance posture: HIPAA · SOC 2 Type II · ISO 27001 · HITRUST · BAA signed at onboarding. PHI never leaves the practice’s EHR environment. The dedicated, remote team works inside the practice’s own system under role-based access,  not a shared offshore pool.

Results vs Industry Benchmark

Six metrics that moved inside 90 days

Industry benchmarks pulled from AMA 2024 PA Survey, KFF 2024 Medicare Advantage data, CAQH 2024 Index, and CMS-0057-F regulatory timelines. Staffingly results are composite outcomes across 5 oncology engagements.

Metric Industry Benchmark Staffingly Result Improvement
Average PA turnaround 5 to 10 business days (AMA 2024) Under 36 hours 78% faster
First-pass approval rate 55 to 70% typical 87% +17 pts
Denial overturn on appeal 50 to 60% industry, 80.7% MA when appealed (KFF) 64% Within range, repeatable
PAs processed per VA per day 8 to 12 in-house typical 20 to 24 +100%
Provider hours saved per week 0 baseline 10 to 12 hours Reclaimed for clinic
Cost per PA vs in-house $10.92 manual (CAQH 2024) 55 to 60% lower Savings reinvested in chair time
Methodology: Composite outcomes across 5 community oncology and infusion engagements running between 2025 and 2026. Turnaround measured from order signed to PA approval letter received. First-pass approval rate excludes resubmissions for missing chart notes. Industry benchmarks cited from AMA 2024 Prior Authorization Physician Survey, KFF 2024 Medicare Advantage analysis, and CAQH 2024 Index.
Savings Dashboard

How does outsourcing oncology prior authorization change the numbers?

Conservative model: 39 PAs/provider/week (AMA 2024) · $10.92 manual cost per PA (CAQH 2024) · Staffingly team rate $349/week. Run it with your numbers →

$0M
Quarterly J-code revenue
protected from retroactive denials
0%
Cost reduction per PA
vs in-house staffing
0 hrs
Physician admin hours
reclaimed per week
0%
First-pass prior auth
approval rate (up from ~52%)
PA Turnaround Time
Before outsourcing
~6 days (144 hrs)
After (Staffingly)
< 36 hrs
75% faster turnaround
CMS-0057-F standard: 7-day / 72-hr expedited (eff. 2026)
Approval Rate Comparison
87% FIRST PASS
Before: ~52%
After: 87%
Overturn: 64%
+35 pp improvement
Annual Cost Model (14 providers)
In-House PA Staff (2 FTE est.)
~$210,000 / yr
Staffingly Outsourced (team rate)
~$90,000 / yr
$120K+ estimated annual savings · flat fee, not % of collections
No revenue-share. No hidden fees.
64% Denial overturn rate on peer-to-peer appeals,  built into every outsourced PA pod
Run Your Savings Model
Why Staffingly Wins Prior Authorization for Oncology Infusion

What separates us from typical vendors

We don't name competitors. Ask your current vendor for proof of all four certifications. We will wait.

Capability Typical Vendor Staffingly
Certification Stack HIPAA training only HIPAA + SOC 2 Type II + ISO 27001 + HITRUST
Clinical Credentials General virtual assistants Overseas-licensed MDs, RNs, PharmDs, billers
Risk-Free Pilot No trial period 2-Week Risk-Free Pilot, full refund if not satisfied
Pricing Transparency Quote-only, hidden setup fees $399/wk single, $349/wk team, $299/wk dept
Oncology Clinical Depth Generalist agents reading scripts NCCN guideline mapping, J-code expertise, biomarker context
AI + Automation

Where AI carries the load, and where licensed humans still own the call

The oncology PA pod uses automation aggressively, but every clinical decision still routes to a licensed human. Here is the split:

What AI handles. Payer portal navigation and form pre-fill, J-code and CPT lookup, NCCN compendia citation matching, denial reason pattern recognition across the last 12 months of decisions, peer-to-peer slot scoring against payer reviewer availability, and clinical packet assembly from the EHR using structured templates. The system also flags which payers are sliding outside the CMS-0057-F 7-day standard so the coordinator can escalate before the deadline lapses.

What licensed humans still own. The clinical narrative in any letter of medical necessity. The judgment call on whether an off-label or off-pathway request is worth pursuing or should be re-routed to an on-pathway alternative. Peer-to-peer execution. Appeals strategy on complex denials, especially second-line biologics. Communication with the practice's oncologists when a payer asks for additional staging or biomarker data.

The AMA 2024 survey reported that 61% of physicians are concerned AI will increase denial rates if payers deploy it without clinical oversight. Staffingly's model is the opposite. AI compresses the clerical work that consumes 13 hours per physician per week. The clinical decision stays with credentialed reviewers who are accountable to the practice's medical director and operate under HIPAA, SOC 2 Type II, ISO 27001, and HITRUST controls.

FAQ

Questions practice operators ask before signing

Why does a J-code chemo PA take weeks when our patient is already ready to start?
This is the single most common frustration oncology staff vent about online. Average J-code PA approval times documented across 2024-2025 ranged from 5 to 15 days, with some Medicare Advantage cases running 60+ days. Our pod compresses that by submitting a complete NCCN-cited packet on the first attempt, monitoring payer dwell time daily, and triggering a peer-to-peer the moment a reviewer flags non-compliance. The CMS-0057-F clock (7 calendar days standard, 72 hours expedited starting January 1, 2026) is enforced from our side, not waited on.
How do you keep an off-pathway NCCN regimen from getting auto-denied?
Practicing oncologists routinely note that payers reject anything that drifts off NCCN Category 1 pathways, even when the off-pathway choice is clinically justified. Our pod builds the letter of medical necessity around the exact NCCN compendia citation, prior line-of-therapy documentation, and biomarker rationale. If the payer reviewer is not an oncologist (a complaint repeatedly raised by physicians), we escalate to a true peer-to-peer with a sub-specialty match request on the record.
Drug shortages keep changing our regimen mid-cycle. How do you handle that on the PA side?
Oncology pharmacists and infusion managers report this constantly: a national shortage forces a substitution, and the original PA no longer covers the new J-code. Our pod tracks active shortages from FDA and ASHP lists, maps them to your formulary, and pre-files amended PAs with the substitute J-code, weight-based dosing, and revised cycle dates. The goal is zero rescheduled infusion chairs because of a paperwork lag.
How do you avoid the 4-week peer-to-peer wait that some payers are quoting?
A widely shared concern in physician communities is that some payers stretch peer-to-peer slots out 3 to 4 weeks, which is fatal in oncology timelines. Our coordinator maintains a live availability grid of payer reviewer slots, books the earliest open window, and escalates inside the payer's own grievance pathway when the offer falls outside the CMS-0057-F decision clock. We also document refusal patterns by payer to support state-level complaints when needed.
Medicare Advantage chemo denials feel different from commercial. Do you handle them differently?
Yes, and this is a recurring theme online. Medicare Advantage carriers issued nearly 53 million PA determinations in 2024, with denial-overturn rates above 80% on appeal. Our pod treats every MA denial as appeal-ready from day one: the original submission includes NCCN citation, Medicare LCD/NCD references, and the specific Chapter 13 manual language the appeal panel reviews. We do not absorb the 60-day clock; we file inside 7 business days with a complete record.
What about CMS-0057-F. Does it actually help oncology in 2026?
Coders and PA leads online are skeptical that operational deadlines alone change behavior. Realistically, the January 2026 operational provisions (7-day standard, 72-hour expedited, specific denial reason codes) tighten timelines but leave appeals to existing law. The January 2027 e-PA API is the bigger lift. Our pod operates inside the 2026 envelope today and is API-ready, so when your payers connect, you do not retool. HIPAA, SOC 2 Type II, ISO 27001, and HITRUST controls govern every step.
What does the 2-week risk-free pilot cover for an oncology infusion center?
We work your live J-code backlog at $399 per week single, $349 per week team, or $299 per week department. You keep every approval we secure. If you are not satisfied at the end of 14 days, you do not pay. The pod works inside OncoEMR, iKnowMed, Flatiron, Epic Beacon, or your platform, under a signed BAA. PHI never leaves your system.

Staffingly charges a flat per-specialist weekly fee,  $399/week for one dedicated remote PA specialist, $349/week for five or more (volume), and $299/week for ten or more (enterprise). There is no percentage of collections, no percentage of revenue recovered, and no per-authorization fee. The outsourcing model is designed for practices that want predictable costs and a dedicated, HIPAA-compliant team rather than a shared offshore pool or a software subscription that still requires in-house staff to run it.

Dan Nandan, CEO Staffingly Inc
Written By
Dan Nandan
President & CEO, Staffingly, Inc.

Dan Nandan is the President and CEO of Staffingly, Inc. With 25+ years in IT consulting and healthcare BPO operations, he was one of the earliest U.S. operators to set up an RPO/BPO delivery network in India over 20 years ago. Today his work centers on AI-driven healthcare workflows and helping practices across North America cut administrative costs without compromising care.

2026 Compliance Verified: HIPAA, SOC 2 Type II, HITRUST, ISO 27001 aligned workflows
Bincy Kuriakose, MSN, RN, Clinical Content Reviewer at Staffingly Inc.
Reviewed By
Bincy Kuriakose, MSN, RN
Clinical Content Reviewer, Staffingly, Inc.
State of Illinois · Registered Professional Nurse
Illinois Dept. of Financial & Professional Regulation

Bincy Shiiju Kuriakose is a Clinical Content Reviewer at Staffingly and a U.S. Licensed Registered Nurse (MSN, RN). NCLEX-RN certified with expertise in hospital nursing, telehealth, and nursing education. PhD scholar in Nursing at Peoples' College of Nursing, Bhopal. Reviews every service page for medical accuracy, compliance, and evidence-based best practices.

Stop losing chair time to prior authorization

Run a 2-week risk-free pilot. We work your real backlog, hit the CMS-0057-F clock from day one, and you keep every approval we secure even if you walk away.

LIVE Monica
Meet Monica AI
Online · Agent ready